Bleximenib (JNJ-75276617) 是一种口服有效的和选择性的 menin-KMT2A 抑制剂，对人、小鼠和狗的 IC50 值分别为 0.1、0.045、≤0.066 nM。Bleximenib 能抑制肿瘤细胞增殖，并诱导细胞凋亡 (apoptosis) 和分化。Bleximenib 可用于白血病等肿瘤的研究。
| 生物活性 |
Bleximenib (JNJ-75276617) is an orally active and selective menin-KMT2A inhibitor, with IC50 values of 0.1 nM, 0.045 nM, and ≤0.066 nM for humans, mice, and dogs, respectively. Bleximenib can inhibit the proliferation and induce apoptosis and differentiation of tumor cells. Bleximenib can be used in the research of tumors such as leukemia. |
|---|---|
| 分子式 |
C32H50FN7O3
|
| 分子量 |
599.78
|
| CAS号 |
2654081-35-1
|
| 中文名称 |
Menin-MLL inhibitor 24
|
| 运输条件 |
Room temperature in continental US; may vary elsewhere. |
| 储存方式 |
2-8˚C, protect from light *In solvent : -80°C, 6 months; -20°C, 1 month (protect from light) |
关注我们
获得KKL MED 最新资讯
客服小K 
客服小K
Data Sheet